Viridian Therapeutics

104 articles with Viridian Therapeutics

• miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership Team

  1/19/2021

  miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced its name change to Viridian Therapeutics, Inc. (“Viridian”).

• miRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease

  12/17/2020

  Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor’s Xtend™ half-life extension technology miRagen expects to file an Investigational New Drug (IND) application for VRDN-002, including half-life extension, by the end of 2021

• miRagen Reports Third Quarter 2020 Financial Results and Provides Corporate Updates

  11/10/2020

  Recently completed acquisition of Viridian Therapeutics, including an anti-IGF-1R monoclonal antibody, VRDN-001, for the potential treatment of thyroid eye disease (TED) Private placement financing proceeds of approximately $91 million positions miRagen to potentially advance multiple compounds through Phase 2 proof of concept studies in TED and expand its orphan disease pipeline

• miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc.

  10/28/2020

  Acquisition includes clinicalstage anti-IGF-1R monoclonal antibody, VRDN-001, intended for the treatment of thyroid eye disease (TED)

• miRagen Announces Internal Review of Preliminary Topline Data for the Phase 2 SOLAR Clinical Trial of Cobomarsen in Patients with Cutaneous T-Cell Lymphoma (CTCL)miRagen decides to discontinue further internal development of cobomarsen

  10/5/2020

  miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that it has conducted an internal review of preliminary topline data from its Phase 2 SOLAR clinical trial of cobomarsen in patients with Cutaneous T-Cell Lymphoma (CTCL).

• 

  BioSpace Movers & Shakers, Sept. 18

  9/18/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• miRagen Announces Leadership Transition and Review of Strategic Alternatives 

  9/14/2020

  miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that its Board of Directors has appointed Lee Rauch,

• miRagen Announces Results of Meeting With FDA Regarding the Design of Pivotal Trial for Cobomarsen in ATLL

  8/20/2020

  miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced that the company held a Type C meeting with the FDA Office of  Oncologic Diseases on August 11, 2020 to discuss miRagen’s future clinical development plans for cobomarsen for the potential treatment of Adult T-Cell Leukemia/Lymphom

• miRagen Reports Second Quarter 2020 Financial Results and Provides Business Updates

  8/5/2020

  miRagen Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary RNA-targeted therapies with a specific focus on microRNAs, reported financial results for the second quarter ended June 30, 2020 and provided business updates.

• miRagen to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

  8/4/2020

  BOULDER, Colo., Aug. 04, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that William S. Marshall, Ph.D., President and Chief Executive Officer of miRagen, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 1:10 p.m. ET. A live webcast of the event will be available on the investors page of the m

• miRagen, Investigators from Goethe University and University Hospital Frankfurt and Servier Publish MRG-110 Phase 1 Pharmacodynamic Biomarker Data in Nucleic Acid Therapeutics

  7/28/2020

  Goethe University, University Hospital Frankfurt and miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that preliminary results from a Phase 1 trial detailing the pharmacodynamic activity of MRG-110 has been published in the peer-reviewed journal Nucleic Acid Therapeutics . “We are pleased to have the

• Cobomarsen Receives Orphan Drug Designation From the U.S. FDA for the Treatment of T-cell Lymphoma

  7/23/2020

  miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that the Food & Drug Administration (FDA) has granted orphan drug designation to cobomarsen, for the treatment of T-cell lymphoma.

• miRagen to Report Second Quarter 2020 Financial Results on August 5, 2020

  7/22/2020

  miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced it will report its second quarter 2020 financial results after the financial markets close on Wednesday August 5, 2020.   The Company’s management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Wednesday August 5, 2020. To access the call, please d

• miRagen Regains Compliance With Nasdaq Listing Requirements

  7/2/2020

  miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that on July 1, 2020 it received written notice from the Nasdaq Listing Qualifications Staff of the NASDAQ Stock Market LLC

• miRagen Announces Encouraging Preclinical Safety and Efficacy Data for its Next-generation miR-29 Replacement Product Candidate Intended for the Treatment of Idiopathic Pulmonary Fibrosis

  6/22/2020

  miRagen Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced preclinical safety and efficacy data for MRG-229, a next-generation miR-29 mimic intended for systemic administration and targeted delivery, in Idiopathic Pulmonary Fibrosis‎.

• miRagen Strengthens Leadership Team with Appointment of Lee Rauch as Chief Operating Officer

  6/18/2020

  miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the appointment of Lee Rauch as Chief Operating Officer, effective immediately.

• miRagen to Host a Key Opinion Leader Call on Idiopathic Pulmonary Fibrosis on Tuesday, June 23rd

  6/16/2020

  miRagen to announce encouraging new preclinical safety and efficacy data for MRG-229 in IPF on June 22nd; and provide an update on the development program during the KOL call

• miRagen to Present at the Jefferies 2020 Virtual Global Healthcare Conference

  5/26/2020

  miRagen Therapeutics, Inc. announced that William S. Marshall, Ph.D., President and Chief Executive Officer of miRagen, will present at the Jefferies Virtual Global Healthcare Conference on Tuesday, June 2, 2020 at 4:00 p.m. ET.

• miRagen Reports First Quarter 2020 Financial Results and Provides Corporate Update

  5/7/2020

  New ATLL data presented in the first quarter; Company plans to request a meeting with the FDA on a regulatory pathway for cobomarsen in ATLL during Q2 2020

• miRagen Therapeutics to Report First Quarter 2020 Financial Results On May 7, 2020

  4/23/2020

  miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced it will report its first quarter 2020 financial results after the financial markets close on Thursday, May 7, 2020.   The Company’s management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Thursday, May 7, 2020. To access the call, please dial 87